Lorus Therapeutics Announces a Key Scientific Publication on Therapeutic siRNA in Cancer TherapyTORONTO, March 1 /CNW/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced publication of scientific data from preclinical studies demonstrating the antitumor activity of its lead small interfering RNA (siRNA) candidate, siRNA-1284.
The article titled "RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo" was published online today in the peer-reviewed journal Anti-Cancer Drugs and will appear in print in the April issue. The paper presents data indicating that siRNA-1284 significantly decreases the expression of the R2 subunit of ribonucleotide reductase in a range of human tumor cell lines in vitro. Lorus' research demonstrates that down-regulation of R2 led to a significant decrease in tumor cell growth and subsequent cell cycle inhibition in vitro. siRNA-1284 also demonstrated potent antitumor activity in vivo in xenograft models of human cancers including renal cell carcinoma, melanoma and colon adenocarcinoma. This article marks Lorus' first major publication of detailed scientific findings for research in the area of RNA interference and siRNA technology.
"We are pleased with the publication of these data in Anti-Cancer Drugs and see it as further validation of Lorus' progress in translating RNA interference science into clinically relevant therapeutics," said Dr. Aiping Young, Lorus' President and CEO. "Gene silencing by RNA interference is a valuable tool in gene function studies and a novel therapeutic approach to drug development. The results presented in this publication further validate R2 as an important antitumor target."
siRNA is a novel class of molecules that can decrease cellular target RNA expression through an antisense process known as RNA interference (RNAi). Because of its target specificity, RNAi is increasingly being examined as a potential therapy for a variety of diseases including cancer. From an evolutionary perspective, RNAi helps protect cells from viruses and transposable genetic elements in addition to carrying out more routine cellular tasks essential to development and growth. In mammalian cells siRNAs have been shown to be the most effective tools for RNAi, allowing for the development of clean and easily regulated methods for disruption of gene expression. siRNA technology allows for a range of new applications including target validation for drug discovery and medical therapeutics.
Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has several product candidates in multiple Phase II clinical trials and has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.
Forward looking statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Posted: March 2007